[go: up one dir, main page]

IS6625A - Bísýklísk sýklóhexýlamín og notkun þeirra sem mótlyf NMDA viðtaka - Google Patents

Bísýklísk sýklóhexýlamín og notkun þeirra sem mótlyf NMDA viðtaka

Info

Publication number
IS6625A
IS6625A IS6625A IS6625A IS6625A IS 6625 A IS6625 A IS 6625A IS 6625 A IS6625 A IS 6625A IS 6625 A IS6625 A IS 6625A IS 6625 A IS6625 A IS 6625A
Authority
IS
Iceland
Prior art keywords
cyclohexylamine
bicyclic
antagonists
nmda receptors
nmda
Prior art date
Application number
IS6625A
Other languages
English (en)
Inventor
Shridhar Nikam Sham
Leslie Scott Ian
Alan Sherer Brian
David Wise Lawrence
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of IS6625A publication Critical patent/IS6625A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS6625A 2000-05-31 2002-11-18 Bísýklísk sýklóhexýlamín og notkun þeirra sem mótlyf NMDA viðtaka IS6625A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20824100P 2000-05-31 2000-05-31
PCT/US2001/014763 WO2001092239A1 (en) 2000-05-31 2001-05-08 Biciclic cyclohexylamines and their use as nmda receptor antogonists

Publications (1)

Publication Number Publication Date
IS6625A true IS6625A (is) 2002-11-18

Family

ID=22773822

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6625A IS6625A (is) 2000-05-31 2002-11-18 Bísýklísk sýklóhexýlamín og notkun þeirra sem mótlyf NMDA viðtaka

Country Status (28)

Country Link
US (1) US6794402B2 (is)
EP (1) EP1286975B1 (is)
JP (1) JP2003535083A (is)
KR (1) KR20030007797A (is)
CN (1) CN1438996A (is)
AP (1) AP2002002697A0 (is)
AT (1) ATE302763T1 (is)
AU (1) AU2001259618A1 (is)
BG (1) BG107375A (is)
BR (1) BR0111301A (is)
CA (1) CA2409006A1 (is)
DE (1) DE60112924T2 (is)
DZ (1) DZ3361A1 (is)
EA (1) EA200201158A1 (is)
EE (1) EE200200667A (is)
ES (1) ES2245985T3 (is)
HR (1) HRP20021018A2 (is)
HU (1) HUP0302323A2 (is)
IL (1) IL153170A0 (is)
IS (1) IS6625A (is)
MA (1) MA26907A1 (is)
MX (1) MXPA02011926A (is)
NO (1) NO20025762L (is)
OA (1) OA12275A (is)
PL (1) PL359260A1 (is)
SK (1) SK16632002A3 (is)
WO (1) WO2001092239A1 (is)
ZA (1) ZA200209325B (is)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02002749A (es) * 2001-03-27 2002-10-28 Warner Lambert Co Derivados de ciclohexilamina como antagonistas del subtipo selectivo del n-metil-d-aspartato.
GB0116594D0 (en) 2001-07-06 2001-08-29 Cancer Res Ventures Ltd Therapeutic compounds
DE10210779A1 (de) 2002-03-12 2003-10-09 Merck Patent Gmbh Cyclische Amide
AU2003233244B2 (en) * 2002-06-07 2010-05-20 Cortical Pty Ltd Therapeutic molecules and methods-1
MXPA05006650A (es) 2002-12-20 2005-09-30 Cancer Rec Tech Ltd Compuestos de 4-(1-(sulfonil)-1h-indol-2-il)-4-(hidroxi)-ciclohexa-2,5-dienona y analogos de los mismos como agentes terapeuticos.
CN101087618A (zh) * 2004-12-23 2007-12-12 航行药物公司 醋酸亮丙瑞林和乙酰胆碱酯酶抑制剂或nmda受体抑制剂在阿尔茨海默氏病治疗中的应用
JP5270943B2 (ja) * 2008-03-28 2013-08-21 大阪瓦斯株式会社 フルオレン誘導体およびこのフルオレン誘導体を用いたアミノ基含有フルオレン誘導体の製造方法
US9345848B2 (en) 2009-10-20 2016-05-24 Sima Patent Ve Lisanslama Hizmetleri Ltd. Sti. Dry powder inhaler
AR080056A1 (es) * 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
KR20150000875A (ko) 2012-01-27 2015-01-05 내셔날 유니버시티 코포레이션 유니버시티 오브 토야마 세린 라세마제 저해제
CN105152966A (zh) * 2015-07-20 2015-12-16 湖南华腾制药有限公司 一种叠氮化合物的制备方法
CN105001118A (zh) * 2015-07-20 2015-10-28 湖南华腾制药有限公司 一种含碘叠氮化合物的制备方法
CN105153020A (zh) * 2015-07-20 2015-12-16 湖南华腾制药有限公司 一种芳香叠氮化合物的制备方法
CN105061254A (zh) * 2015-07-20 2015-11-18 湖南华腾制药有限公司 一种含溴叠氮化合物的合成方法
WO2018033525A1 (en) * 2016-08-16 2018-02-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Agonists or partial agonists of the histamine site of the nmda receptor for use in the treatment of central nervous system diseases
CN107043335A (zh) * 2017-05-31 2017-08-15 湖南华腾制药有限公司 一种2‑氟苯基叠氮化合物的制备方法
WO2019043217A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROBENZIMIDAZOLONES
WO2025232878A1 (zh) * 2024-05-09 2025-11-13 苏州旺山旺水生物医药股份有限公司 一类含取代的苯基的胺类化合物、其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4438055A1 (de) * 1994-10-25 1996-05-02 Thomae Gmbh Dr K Ring- und N-substituierte N-Benzyl-cycloalkylamine, ihre Salze mit physiologisch verträglichen organischen oder anorganischen Säuren, Verfahren zur Herstellung dieser Verbindungen und diese enthaltende Arzneimittel
DE19812331A1 (de) * 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
EP0982026B1 (en) 1998-08-18 2006-05-17 F. Hoffmann-La Roche Ag Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers

Also Published As

Publication number Publication date
ATE302763T1 (de) 2005-09-15
AU2001259618A1 (en) 2001-12-11
NO20025762D0 (no) 2002-11-29
HRP20021018A2 (en) 2004-02-29
ES2245985T3 (es) 2006-02-01
WO2001092239A1 (en) 2001-12-06
DE60112924T2 (de) 2006-03-16
KR20030007797A (ko) 2003-01-23
CN1438996A (zh) 2003-08-27
JP2003535083A (ja) 2003-11-25
ZA200209325B (en) 2004-02-16
PL359260A1 (en) 2004-08-23
US20030236252A1 (en) 2003-12-25
AP2002002697A0 (en) 2002-12-31
HUP0302323A2 (hu) 2003-10-28
EE200200667A (et) 2004-06-15
EP1286975B1 (en) 2005-08-24
US6794402B2 (en) 2004-09-21
EP1286975A1 (en) 2003-03-05
DE60112924D1 (de) 2005-09-29
BG107375A (bg) 2003-09-30
MXPA02011926A (es) 2003-04-22
SK16632002A3 (sk) 2003-08-05
OA12275A (en) 2003-12-11
CA2409006A1 (en) 2001-12-06
EA200201158A1 (ru) 2003-04-24
BR0111301A (pt) 2003-06-10
IL153170A0 (en) 2003-06-24
MA26907A1 (fr) 2004-12-20
NO20025762L (no) 2003-01-09
DZ3361A1 (fr) 2001-12-06

Similar Documents

Publication Publication Date Title
IS6625A (is) Bísýklísk sýklóhexýlamín og notkun þeirra sem mótlyf NMDA viðtaka
IS7801A (is) Púrín efnasambönd og notkun þeirra sem kannabinóíð viðtaka bindla
IS7040A (is) 5-HT viðtakabindlar og notkun þeirra
IS7216A (is) Bensamíð og heteróarýlamíð sem P2X7 viðtaka mótlyf
IS2529B (is) Nýjar spírótrísýklískar afleiður og notkun þeirra sem fosfódíesterasa-7-hindrar
PL374832A1 (pl) Nowe podstawione benzoimidazolowe postacie dawkowe i sposoby ich stosowania
AU2003238597A8 (en) Benzimidazole compounds and their use as estrogen agonists/antagonists
EE200000778A (et) 4-bensüülpiperidiinalküülsulfoksiidi heterotsüklid ja nende kasutamine NMDA retseptori alaliikide suhtes selektiivsete antagonistidena
PT1379504E (pt) Derivados bipiperidinilo e sua utilização como inibidores de receptores de quimioquinas
EP1436258A4 (en) PH VALVE DEPENDENT NMDA RECEPTOR ANTAGONISTS
IL188844A0 (en) Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists
IS6656A (is) Útskiptar kínasólínafleiður og notkun þeirra sem hemla
IS6802A (is) 3-arýlindólafleiður og notkun þeirra sem CB2 viðtakagerandefni
SI1170288T1 (en) Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists
AU2002213409A1 (en) Galphaqproetin variants and their use in the analysis and discovery of agonists and antagonists of chemosensory receptors
NO20025136L (no) Cykloheksylaminderivat som subtype selektive NMDA- reseptorantagonister
IL169336A0 (en) Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
HUP0401756A3 (en) Substituted benzimidazole compounds and their use
AU2003260072A8 (en) Antagonists of chemokine receptors
AU2003279841A8 (en) Uses of human zven antagonists
HUP0301551A3 (en) New use of 5ht3 and neuronal nicotinicreceptor antagonist 1-amino-alkycyclohexanes
GB0011817D0 (en) Antagonists of integrin receptors
HU0104019D0 (en) Prophylactic use of n-methyl-d-aspartate (nmda) antagonists
PT1448566E (pt) Antagonistas do receptor quimioquina e metodos de utilizacao do mesmo
PL376075A1 (en) Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists